Biotech company Prolor has reported positive pre clinical trial results for its hemophilia drug known a Factor Vlla. The modified drug boasts a longer duration and half life of clotting activity versus current versions.
The animal trials of Factor Vlla were conducted in hemophilic mice, and compared side by side with current versions of recombinant Factor Vlla. The advanced Factor Vlla-CTP showed significantly improved results as compared to the current commercial version of the drug, which is used to treat acute bleeding in hemophiliacs and to prevent bleeding in patients with hemophilia A and B in which treatment with Factor IX or Factor VIII is ineffective. The results were consistent with pre clinical trials and are considered to be positive by the company. They expect Factor VIIa to be highly competitive in the $2 billion market for hemophilia treatments.